Literature DB >> 12628653

Synthesis and anticancer activity of 2-amino-8-chloro-5,5-dioxo[1,2,4]triazolo[2,3-b][1,4,2]benzodithiazine derivatives.

Elzbieta Pomarnacka1, Maria Gdaniec.   

Abstract

A new series of 1-(6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)-4-arylsemicarbazides (4-16) were obtained. Intramolecular ring closure in semicarbazides 4-16 upon treatment with phosphorus oxychloride resulted in the formation of 2-amino-8-chloro-5,5-dioxo[1,2,4]triazolo[2,3-b][1,4,2]benzodithiazines 17-29 with potential antitumor activity. The structures of these compounds were confirmed on the basis of elemental analysis, spectral data and X-ray analysis. Compounds 17-29 were screened at the US National Cancer Institute (NCI) for their activities against a panel of 59 tumor cell lines, and relationships between structure and antitumor activity in vitro are discussed. The benzodithiazines 18, 19, 23, 28 and 29 were inactive, whereas the other compounds exhibited reasonable activity against numerous human tumor cell lines. The prominent compound 17 showed significant activity against the leukemia SR cell line (log GI(50)=-7.67, log TGI=-6.90 and log LC(50)=-4.77).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628653     DOI: 10.1016/s0968-0896(02)00638-7

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Synthesis and QSAR study of novel 6-chloro-3-(2-Arylmethylene-1-methylhydrazino)-1,4,2-benzodithiazine 1,1-dioxide derivatives with anticancer activity.

Authors:  Jarosław Sławiński; Beata Żołnowska; Zdzisław Brzozowski; Anna Kawiak; Mariusz Belka; Tomasz Bączek
Journal:  Molecules       Date:  2015-04-01       Impact factor: 4.411

2.  Synthesis, cytotoxicity testing, and structure-activity relationships of novel 6-chloro-7-(4-phenylimino-4H-3,1-benzoxazin-2-yl)-3-(substituted)-1,4,2-benzodithiazine 1,1-dioxides.

Authors:  Elżbieta Pomarnacka; Anita Kornicka; Anna Kuchnio; Maike Heinrichs; Renate Grünert; Maria Gdaniec; Patrick J Bednarski
Journal:  Arch Pharm (Weinheim)       Date:  2011-05-25       Impact factor: 3.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.